Detalhe da pesquisa
1.
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Cancer
; 127(14): 2432-2441, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33740262
2.
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med
; 379(26): 2495-2505, 2018 12 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30345884
3.
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
Gynecol Oncol
; 163(1): 41-49, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34353615
4.
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
Lancet Oncol
; 19(8): 1126-1134, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30026002
5.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(9): 1274-1284, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28754483
6.
Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.
J Child Psychol Psychiatry
; 57(6): 717-28, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26871297
7.
Stress levels experienced by parents of children with and without attention-deficit/hyperactivity disorder during the back-to-school period: results of a European and Canadian survey.
Int J Psychiatry Clin Pract
; 19(1): 8-17, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25195767
8.
Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial.
Eur Child Adolesc Psychiatry
; 23(2): 61-8, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23708466
9.
Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
Clin Gastroenterol Hepatol
; 9(8): 670-678.e3, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21642014
10.
Certolizumab pegol for the treatment of Crohn's disease.
N Engl J Med
; 357(3): 228-38, 2007 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-17634458
11.
Maintenance therapy with certolizumab pegol for Crohn's disease.
N Engl J Med
; 357(3): 239-50, 2007 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-17634459
12.
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
Clin Gastroenterol Hepatol
; 8(7): 600-9, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20117244
13.
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study.
Clin Gastroenterol Hepatol
; 8(8): 696-702.e1, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20363366
14.
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
Am J Gastroenterol
; 105(7): 1574-82, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20234346
15.
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
J Clin Oncol
; 38(30): 3528-3537, 2020 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32749942
16.
Reply to S. Gulia et al.
J Clin Oncol
; 39(3): 256, 2021 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33326256
17.
A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
J Am Acad Child Adolesc Psychiatry
; 54(11): 916-25.e2, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26506582
18.
Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
Eur Neuropsychopharmacol
; 24(12): 1861-72, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25453486
19.
A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
CNS Drugs
; 27(9): 743-51, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23801529
20.
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
CNS Drugs
; 27(12): 1081-92, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23959815